Total Funding
60
51
Total FundingGrant raised
Growth Score
-2 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
113218
OrPro Therapeutics develops recombinant thioredoxin for the treatment of cystic fibrosis.
Peter Heifetz: CEO
Jeff Raser: COO
About the Company
OrPro Therapeutics,Inc. is a pre-clinical stage biopharmaceutical company headquartered in San Diego, CA. The company’s goal is to develop a breakthrough class of safe, well-tolerated and effective inhaled non-systemic drugs based on the thioredoxin active site for the treatment of patients with cystic fibrosis (CF) and other serious obstructive
pulmonary diseases.
